IDRx
Plymouth, Massachusetts, United States · Biotechnology, Health Care, Pharmaceutical · 45 employees
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Inspired by a few curative combination regimens in cancer and the successful drug cocktails purposely engineered in other disease areas such as cystic fibrosis and antivirals, IDRx aims to address the limitations of today’s precision cancer medicines
Funding history
- Series series b — $120.0M — Aug 2024
- Series series a — $122.0M — Aug 2022
Recent signals
- Aug 07, 2024: Raised $120.0M in Series series b
- Mar 27, 2024: IDRx Appoints Dr. David P. Kerstein as Chief Medical Officer
- Mar 12, 2024: IDRx Appoints Tim Clackson as CEO and Brad Dahms as CFO and CBO
- Mar 12, 2024: IDRx Appoints Tim Clackson as Chief Executive Officer and Brad Dahms as Chief Financial Officer
- Aug 02, 2022: Raised $122.0M in Series series a
See plans & pricing → Track IDRx’s funding, hiring, and signals — with verified contacts — on Fundz.